Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.

Zhu X, Kim DW, Zhao L, Willingham MC, Cheng SY.

Endocr Relat Cancer. 2016 Jul;23(7):521-33. doi: 10.1530/ERC-16-0103. Epub 2016 Jun 7.

PMID:
27267120
2.

Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.

Manohar PM, Beesley LJ, Taylor JM, Hesseltine E, Haymart MR, Esfandiari NH, Hanauer DA, Worden FP.

J Thyroid Disord Ther. 2015 Aug;4(3). pii: 188. Epub 2015 Jul 17.

3.

Mouse models of thyroid cancer: A 2015 update.

Kirschner LS, Qamri Z, Kari S, Ashtekar A.

Mol Cell Endocrinol. 2016 Feb 5;421:18-27. doi: 10.1016/j.mce.2015.06.029. Epub 2015 Jun 27.

PMID:
26123589
4.

Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY.

Neoplasia. 2014 Sep;16(9):757-69. doi: 10.1016/j.neo.2014.08.003.

5.

Genetics and epigenetics of sporadic thyroid cancer.

Vu-Phan D, Koenig RJ.

Mol Cell Endocrinol. 2014 Apr 5;386(1-2):55-66. doi: 10.1016/j.mce.2013.07.030. Epub 2013 Aug 8. Review.

6.

Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.

Fozzatti L, Park JW, Zhao L, Willingham MC, Cheng SY.

PLoS One. 2013 Jun 26;8(6):e67954. doi: 10.1371/journal.pone.0067954. Print 2013.

7.

Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models.

Kim WG, Zhao L, Kim DW, Willingham MC, Cheng SY.

Thyroid. 2014 Feb;24(2):260-9. doi: 10.1089/thy.2013.0054. Epub 2013 Sep 4.

8.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(2):405-6.

9.

Thyroid cancer: pathogenesis and targeted therapy.

Liebner DA, Shah MH.

Ther Adv Endocrinol Metab. 2011 Oct;2(5):173-95. doi: 10.1177/2042018811419889.

10.

Mouse models of follicular and papillary thyroid cancer progression.

Russo MA, Antico Arciuch VG, Di Cristofano A.

Front Endocrinol (Lausanne). 2012 Jan 10;2:119. doi: 10.3389/fendo.2011.00119. eCollection 2011.

11.

Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.

Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, Irifune K, Ito R, Miyazaki T, Okura T, Higaki J.

Int J Oncol. 2012 Aug;41(2):449-56. doi: 10.3892/ijo.2012.1462. Epub 2012 May 8.

12.

Thyroid hormone receptors and cancer.

Kim WG, Cheng SY.

Biochim Biophys Acta. 2013 Jul;1830(7):3928-36. doi: 10.1016/j.bbagen.2012.04.002. Epub 2012 Apr 6. Review.

13.

Modeling follicular thyroid cancer for future therapies.

Zhu X, Cheng SY.

Am J Cancer Res. 2012;2(2):130-40. Epub 2012 Feb 15.

14.

Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.

Lu C, Zhu X, Willingham MC, Cheng SY.

Oncogene. 2012 Apr 19;31(16):2007-16. doi: 10.1038/onc.2011.390. Epub 2011 Sep 12.

15.
16.

Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer.

Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng SY, Ringel MD.

Oncogene. 2011 Oct 20;30(42):4307-15. doi: 10.1038/onc.2011.136. Epub 2011 May 2.

17.

Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis.

Lu C, Cheng SY.

Steroids. 2011 Aug;76(9):885-91. doi: 10.1016/j.steroids.2011.03.016. Epub 2011 Apr 5. Review.

18.
19.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M.

J Clin Endocrinol Metab. 2011 Apr;96(4):E577-85. doi: 10.1210/jc.2010-2644. Epub 2011 Feb 2.

20.

Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth.

Couderc C, Poncet G, Villaume K, Blanc M, Gadot N, Walter T, Lepinasse F, Hervieu V, Cordier-Bussat M, Scoazec JY, Roche C.

Am J Pathol. 2011 Jan;178(1):336-44. doi: 10.1016/j.ajpath.2010.11.023. Epub 2010 Dec 23.

Items per page

Supplemental Content

Write to the Help Desk